focus trial semaglutide Efficacy and safety of once-weekly 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B A Pharmacological and Clinical Overview

"This finding potentially opens the possibility of an entirely new pharmacological treatment paradigm, which could be used in conjunction with conventional methods, such as behavior therapy and group support." Potential limitations The study was limited by its relatively small number of patients, the researchers acknowledged

It will also be critical to link these sensory shifts to real-world eating patterns and long-term outcomes. Moser said researchers could also try to identify which patients experience the greatest benefits related to taste in hopes of personalizing therapy in the future

This metabolic pathway creates a sustained release of L-arginine in your body

Maher, S

Semaglutide tends to produce a more gradual onset of side effects, allowing many patients to adapt as their bodies adjust to the medication